Profitability Metrics

Gross Margin
69.76%
Operating Margin
44.64%
Net Margin
35.96%

Efficiency Metrics

Revenue per Expense Ratio
1.81
R&D as % of Revenue
12.04%

Earnings Quality

EBITDA Margin
54.26%
Income Tax Rate
18.23%
EPS
11.8600000000

Balance Sheet Analysis

Current Ratio
1.27
Cash Ratio
0.60
Working Capital
$34.45B
Debt to Equity
0.36
Debt to Assets
19.11%
Equity Ratio
52.42%

Cash Flow Analysis

Operating Cash Flow Ratio
48.36%
Free Cash Flow Ratio
30.22%
CapEx to Revenue
18.14%
Dividends Paid
$21.77B
Stock Buybacks
$17.25B
Total Shareholder Returns
$39.03B
Cash Position Change
-47.23%

Key Takeaways (2024 FY)

  • Maintained positive net income growth despite revenue changes
  • Increased dividend payments by 10.18%
  • Increased R&D investment by 8.51%

Detailed Growth Metrics

Core Performance

Revenue
15.67%
Net Income
21.80%
EPS
22.02%
Operating Income
23.62%

Operational Efficiency

R&D Expenses
8.51%
SG&A Expenses
5.71%
Operating Cash Flow
35.36%
Free Cash Flow
24.54%

Balance Sheet Health

Assets
24.32%
Debt
23.18%
Book Value per Share
30.45%
Inventory
-50.16%

Shareholder Returns

Dividends per Share
10.18%
Shares Outstanding
-0.20%

Long Term Trends

3Y Revenue/Share
48.11%
5Y Revenue/Share
101.13%
3Y Dividend/Share
33.83%
5Y Dividend/Share
62.77%